Linfomi recidivati/refrattari, nuove speranze con gli anticorpi bispecifici

The treatment of lymphomas has made significant progress in recent times. Among the most exciting new drugs for the treatment of these hematological malignancies are undoubtedly bispecific antibodies. We discuss this in this interview with an expert, Professor Umberto Vitolo (Head of Experimental Clinical Studies in Hematology at the Candiolo Institute - Piedmont Foundation for Oncology – IRCCS), whom we met in Rome on the sidelines of the Current Challenges in Hematology conference, recently held in Rome and now in its second edition.